Ⅳ期寡转移NSCLC放疗及最佳介入时机研究

doi:10.3760/cma.j.issn.1004-4221.2018.11.005

摘要
图/表
参考文献()
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的明确胸部放疗在Ⅳ期寡转移NSCLC治疗中的意义,探索胸部放疗最佳介入时机。方法将2008-2014年山西省肿瘤医院192例Ⅳ期“寡转移”NSCLC患者随机均分为单纯化疗组、放疗早期介入组、放疗中期介入组、放疗晚期介入组。Kanplan-Meier法生存分析。结果 192例寡转移Ⅳ期NSCLC中位生存期为14.50个月,1、2、3年生存率分别为57.4%、24.0%、10.7%。单纯化疗组、放疗早期介入组、放疗中期介入组、放疗晚期介入组中位生存期分别为10、21、18、13个月,1年生存率分别为34%、73%、71%、51%,2年生存率分别为10%、40%、32%、13%,3年生存率分别为0%、24%、16%、3%(P=0.000)。放疗剂量≥60 Gy与<60 Gy者的中位生存期分别为21个月与13个月,1年生存率分别为76%与53%,2年生存率分别为34%与21%,3年生存率为17%与10%(P=0.002)。结论对于Ⅳ期寡转移NSCLC患者,胸部病灶放疗的较早期介入和高剂量放疗能提高患者局控率,延长生存期。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李瑞宁
	李晓敏
	李琦
	任雅琼
	武亚娟
	任跃君

关键词 ：肺肿瘤/放射疗法, 寡转移, 介入时机, 预后

Abstract：Objective To clarify the significance of chest radiotherapy in the treatment of oligometastatic stage ⅠV non-small cell lung cancer (NSCLC) and to explore the optimal time of interventional therapy during chest radiotherapy. Methods A total of 192 patients with oligometastatic stage ⅠV NSCLC admitted to Shanxi Provincial Cancer Hospital from 2008 to 2014 were randomly and evenly divided into the chemotherapy alone, radiotherapy+ early intervention, radiotherapy+ middle intervention and radiotherapy+ late intervention groups. Survival analysis was performed with Kanplan-Meier method. Results The median survival of 192 patients with oligometastatic stage ⅠV NSCLC was 14.50 months, and the 1-,2-and 3-year survival rates were 57.4%,24.0% and 10.7%, respectively. The median survivalin the chemotherapy alone, radiotherapy+ early intervention, radiotherapy+ middle intervention and radiotherapy+ late intervention groups was 10,21,18 and 13 months, respectively. The 1-year survival rates were 34%,73%,71% and 51%,10%,40%,32% and 13% for the 2-year survival rates, and 0%,24%,16% and 3% for the 3-year survival rates (P=0.000).The median survival of patients with radiotherapy dose ≥ 60 Gy and< 60 Gy was 21 and 13 months, 76% and 53% for the 1-year survival rates, 34% and 21% for the 2-year survival rates, and 17% and 10% for the 3-year survival rates (P=0.002). Conclusion Early interventional therapy and high-dose radiotherapy can improve the local control rate and prolong the survival time of patients with oligometastatic stage ⅠV NSCLC.

Key words： Lung neoplasm/radiotherapy Oligometastasis Intervention timing Prognosis

收稿日期: 2017-12-06

通讯作者: 李晓敏,Email:xmli11@126.com

引用本文:

李瑞宁,李晓敏,李琦等. Ⅳ期寡转移NSCLC放疗及最佳介入时机研究[J]. 中华放射肿瘤学杂志, 2018, 27(11): 975-979.

Li Ruining,Li Xiaomin,Li Qi et al. The clinical study of chest radiotherapy and optimal timing of intervention in oligometastatic stage Ⅳ NSCLC[J]. Chinese Journal of Radiation Oncology, 2018, 27(11): 975-979.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2018.11.005 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2018/V27/I11/975

[1] Chen VW,Bernardo A.Ruiz MD PhD,Msph M C H,et al. Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries:AJCC staging and collaborative stage data collection system[J].Cancer,2014,120(S23):3781-3792.DOI:10.1002/cncr.29045.
[2] Luketich JD,Martini MN,Ginsberg RJ,et al. Successful treatment of solitary extracranial metastases from non-small cell lung cancer[J].Ann Thorac Surg,1995,60(6):1609-1611.DOI:10.1016/0003-4975(95)00760-1.
[3] Azzoli CG,Temin S,AliffT,et al2011 focused update of 2009 American society of clinical oneology clinical practice guideline update on chemotherapy for stage Ⅳ non-small cell lung cancer[J].Clin Oncol,2011,29(28):3825-3831.DOI:10.1200/JOP.2011.000374.
[4] Salama JK,Schild SE.Radiation therapy for oligometastasic non-small cell lung cancer[J].Cancer Metest Rev,2015,34(2):183-193.
[5] Shimada Y,Saji H,Kakihana M,et al. Survival outcomes for oligometastasis in resected non-small cell lung cancer[J].Asian Cardiovasc Thorac Ann,2015,23(8):937-944.DOI:10.1177/0218492315596463.
[6] Eberhardt WE,Mitchell A,Crowley J,et al. The IASLC lung cancer staging project:proposals for the Revision of the M descriptors in the forthcoming eight edition of the TNM classification of lung cancer[J].J Thorac Oncol,2015,10(11):1515-1522.DOI:10.1097/JTO.0000000000000673.
[7] Suzuki H,Yoshino I.Approach for oligometastasis in non-small cell lung cancer[J].General Thorac Cardiovasc Surg,2016,64(4):192-196.DOI:10.1007/s11748-016-0630-7.
[8] Griffioen GH,Toguri D,Dahele M,et al. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC):patient outcomes and prognostic factors[J].Lung Cancer,2013,82(1):95-102.DOI:10.1016/j.lungcan.2013.07.023.
[9] Gray PJ,Mak RH,Yeap BY,et al. Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival[J].Lung Cancer,2014,85(2):239-44.DOI:10.1016/j.lungcan.2014.06.001.
[10] Shimada Y,Saji H,Kakihana M,et al. Survival outcomes for oligometastasis in resected non-small cell lung cancer[J].Asian Cardiovasc Thorac Ann,2015,23(8):937-944.DOI:10.1177/0218492315596463.
[11] Palma DA.An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer[J].Clin Lung Cancer,2014,15(5):346-355.DOI:10.1016/j.cllc.2014.04.003.
[12] Bai H,Xu J,Yang H,et al. Survival prognostic factors for patients with synchronous brain oligometastatic non-small-cell lung carcinoma receiving local therapy[J].Oncotarg Ther,2016,9(1):4207-4213.DOI:10.2147/OTT.S106696.
[13] Cheruvu P,Su KM,Metcalfe J,et al. Comparison of outcomes in patients with stage Ⅲ versus limited stage Ⅳnon-small cell lung cancer[J].Radiat Oncol,2011,6(1):80.DOI:10.1186/1748-717X-6-80.
[14] Chang HJ,Hui-Ling K,Cheng-Yen L,et al. Hypofractionated radiotherapy for primary or secondary oligometastatic lung cancer using Tomotherapy[J].Radiat Oncol,2012,7(1):222.DOI:10.1186/1748-717X-7-222.
[15] Hasselle MD,Haraf DJ,Rusthoven KE,et al. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer[J].J Lung Cancer,2012,7(2):376-381.DOI:10.1097/JTO.0b013e31824166a5.
[16] Lopez-Guerra JL,Gomez D,Zhuang Y,et al. Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis[J].Int J Radiat Oncol Biol Phys,2012,84(1):e61-e67.DOI:10.1016/j.ijrobp.2012.02.054.
[17] De Ruysscher D,Wanders R,BA Van,et al. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases:long-term results of a prospective phase Ⅱ trial (Nct01282450)[J].J Lung Cancer,2012,7(10):1547.DOI:10.1097/JTO.0b013e318262caf6.
[18] 吕家华,李涛,刘丽,等.Ⅳ期寡转移NSCLC同期放化疗后巩固化疗前瞻性Ⅱ期临床研究[J].中华放射肿瘤学杂志,2015,24(6):611-614.doi:10.3760/cma.j.issn.1004-4221.2015.06.002.
Lyu JH,Li T,Liu L,et al. A prospective phase Ⅱ study of consolidation chemotherapy after concurrent chemoradiotherapy for oligometastatic stage ⅠV non-small cell lung cancer[J].Chin J Radiat Oncol,2015,24(6):611-614.DOI:10.3760/cma.j.issn.1004-4221.2015.06.002.